Medicare GLP-1 Bridge begins, covering the Zepbound KwikPen only

Medicare's new $50-a-month obesity drug demonstration, the Medicare GLP-1 Bridge, launched July 1, 2026 and runs through December 31, 2027 ^[1][6]. Medicare's beneficiary fact sheet names exactly three covered products: Foundayo (orforglipron) tablets, Wegovy (semaglutide) injection or tablets, and Zepbound (tirzepatide) KwikPen only ^[4]. The single-dose Zepbound pen and Zepbound vials are not covered ^[2][4].

Federal law has barred Part D from paying for drugs used for weight loss since the benefit began, so people on Medicare could only get GLP-1s covered for another approved use, such as type 2 diabetes, cardiovascular risk reduction, or sleep apnea ^[3]. CMS built the Bridge using Section 402 demonstration authority, which lets the Secretary test changes in payment methods ^[6]. The program runs nationwide and sits outside the Part D benefit, so Part D plans do not have to opt in and do not carry the financial risk ^[6].

What's covered, and what isn't

The device detail matters. The Zepbound KwikPen is a multi-dose pen that contains all four weekly doses for a month; pen needles are sold separately and are not included ^[5]. Lilly's Medicare page tells patients to check that an existing prescription is written for the KwikPen and not the single-dose pen or vial ^[5]. Because the covered list includes only those three products, brands used mainly for diabetes — Ozempic and Rybelsus (semaglutide) and Mounjaro (tirzepatide) — are not on it ^[4].

Eligibility has four parts. You need Part D coverage through a standalone drug plan or a Medicare health plan with drug coverage; certain plan types, including private fee-for-service plans, cost contract plans, and PACE organizations, do not qualify ^[4]. You must not already be receiving a GLP-1 paid for by your Part D plan for any reason ^[4]. You must not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — in those cases your plan may already cover a GLP-1 ^[2][4]. And you must be 18 or older with a BMI of 35 or higher; or BMI 30 or higher with diastolic heart failure, uncontrolled high blood pressure, or chronic kidney disease stage 3a or above; or BMI 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease ^[2][4].

A prescriber must send the prescription to a pharmacy and complete a prior authorization, certifying the drug is used alongside a diet-and-exercise program ^[2]. The pharmacy may ask for your Medicare Number or the last four digits of your Social Security Number, and CMS mails a letter confirming coverage ^[2][4]. Pharmacies route these claims through a separate processor using BIN 028918, PCN MEDDGLP1BR, group GLP1Bridge ^[5]. The authorization holds through December 31, 2027, including refills and dose increases, unless you switch to a different GLP-1 ^[2].

Why it matters for patients

The $50 price is flat regardless of income, but the money does not behave like normal Part D spending ^[4]. The Part D deductible does not apply, none of the $50 counts toward true out-of-pocket (TrOOP) costs, and there is no low-income subsidy for LIS beneficiaries ^[6]. These drugs also cannot be spread out under the Medicare Prescription Payment Plan ^[4]. For someone with other expensive prescriptions, that means Bridge spending will not move them closer to the yearly out-of-pocket cap.

The device restriction is the practical trap. A patient approved for the Bridge whose prescription is written for a single-dose Zepbound pen or vial will not have it covered ^[2][4]. Cost has been a real barrier: KFF polling found 56% of GLP-1 users said the drugs were hard to afford, including one in four who said "very difficult" ^[3]. Medicare gross spending on GLP-1s for approved uses reached $27.5 billion on 21.8 million claims in 2024 ^[3].

What happens next

The Bridge was originally scheduled to end December 31, 2026, then extended through December 31, 2027 ^[3]. It was meant to hand off to the broader BALANCE Model in Part D starting January 2027, but CMS announced on April 21, 2026 that BALANCE in Medicare is indefinitely delayed; CMS says the extension lets it collect utilization data for plans ahead of any future BALANCE launch ^[3][6]. BALANCE is proceeding for state Medicaid agencies, running from May 2026 through December 2031, with state applications due July 31, 2026 ^[3]. Separately, a negotiated Medicare price for semaglutide takes effect in 2027 ^[3]. What happens to Bridge enrollees after 2027 is not yet known.